NASDAQ · ANIX
Healthcare · Biotechnology
$3.02
Up+$0.07 (+2.37%)
Updated Oct 7, 2026, 3:21 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANIX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ANIX closed at $3.02 after 21 trading sessions, up 4.14% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $2.95 | $3.11 | $2.87 | $3.02 | 344.96K |
| Oct 5, 2026 | $2.98 | $2.99 | $2.875 | $2.95 | 369.46K |
| Oct 2, 2026 | $2.83 | $2.95 | $2.77 | $2.95 | 434.48K |
| Oct 1, 2026 | $2.93 | $2.93 | $2.735 | $2.77 | 290.39K |
| Sep 30, 2026 | $2.85 | $2.945 | $2.81 | $2.93 | 430.33K |
| Sep 29, 2026 | $2.79 | $2.85 | $2.72 | $2.85 | 183.25K |
| Sep 28, 2026 | $2.78 | $2.83 | $2.70 | $2.79 | 305.83K |
| Sep 25, 2026 | $2.85 | $2.87 | $2.69 | $2.78 | 360.85K |
| Sep 24, 2026 | $2.74 | $2.81 | $2.715 | $2.78 | 257.68K |
| Sep 23, 2026 | $2.77 | $2.8108 | $2.62 | $2.75 | 391.16K |
| Sep 22, 2026 | $2.73 | $2.79 | $2.68 | $2.79 | 434.62K |
| Sep 21, 2026 | $2.82 | $2.82 | $2.66 | $2.70 | 476.34K |
| Sep 18, 2026 | $2.78 | $2.79 | $2.69 | $2.77 | 315.22K |
| Sep 17, 2026 | $2.66 | $2.76 | $2.64 | $2.76 | 345.82K |
| Sep 16, 2026 | $2.70 | $2.72 | $2.56 | $2.60 | 557.5K |
| Sep 15, 2026 | $2.80 | $2.80 | $2.66 | $2.69 | 353.79K |
| Sep 14, 2026 | $2.79 | $2.88 | $2.76 | $2.80 | 376.44K |
| Sep 11, 2026 | $2.87 | $2.88 | $2.72 | $2.76 | 389.37K |
| Sep 10, 2026 | $2.76 | $2.8085 | $2.66 | $2.75 | 400.15K |
| Sep 9, 2026 | $2.92 | $2.969 | $2.79 | $2.83 | 478.82K |
| Sep 8, 2026 | $3.10 | $3.20 | $2.875 | $2.90 | 442.11K |
The latest Smart Investors Daily articles mentioning ANIX.
Company
Market Activity
Research & News
ANIX research
Company profile and research snapshot.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 22, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 31, 2026 | D. Boral Capital | Buy | — |
| Feb 4, 2026 | D. Boral Capital | Buy | — |
| Dec 12, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 1, 2026
The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is evaluating a novel CAR-T therapy targeting follicle stimulating hormone receptor (FSHR), which is expressed on ovarian
Benzinga · Sep 22, 2026
HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and lowers the price target from $7 to $6.
Yahoo · Sep 21, 2026
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued Patent Number 2020221280 related to Anixa's breast cancer vaccine technology, exclusively licensed from Cleveland Clinic. This composition-of-matter patent protects the Company's novel approach to breast cancer prevention and treatment in Australia through 2040, addressing a disease for which no preventive vacci
Benzinga · Sep 21, 2026
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANIX.
